PubMed چکیده/رکورد

Patient-derived mesenchymal stromal cells establish an IL-6 axis that marks progression from smouldering to active multiple myeloma.

استودیوی صوتی مقاله

پخش حرفه‌ای فارسی و انگلیسی

در حال بررسی نسخه‌های صوتی ذخیره‌شده…

صوت تولیدشده با هوش مصنوعی است. برای کاربرد علمی یا درمانی، متن و منبع اصلی را بررسی کنید.
خواندن هوشمند فارسی و انگلیسی در حال آماده‌سازی صداهای مرورگر…
تنظیم صدای طبیعی و سرعت

صداهایی که در نامشان «Natural»، «Neural» یا «Online» دیده می‌شود معمولاً طبیعی‌ترند. انتخاب صدا به صداهای نصب‌شده در ویندوز و مرورگر شما بستگی دارد.

چکیده اصلی

IL-6 signalling in the bone marrow (BM) is compartmentalised. Different cell populations within the BM niche contribute distinct components of the IL-6 signalling network, yet how their roles change during myeloma progression has remained unclear. We examined how the respective contributions of mesenchymal stromal cells (MSCs) and primary multiple myeloma (MM) cells to the IL-6 signalling machinery change during disease progression. MSCs were identified as the principal source of IL-6, whereas MM cells secreted minimal IL-6 but were the primary source of soluble IL-6 receptor (sIL-6R). This functional interplay, with MSCs supplying the ligand and MM cells providing the soluble receptor, establishes a paracrine IL-6 trans-signalling axis. The contribution of MM cells to this axis increases significantly with disease stage: cells from patients with active MM secreted substantially greater quantities of sIL-6R than those from patients with smouldering disease, identifying sIL-6R as a marker of biologically active disease. This increase is mirrored by higher basal IL-6 secretion from MSCs in advanced disease, demonstrating augmentation of the IL-6 signalling pathway as disease progresses. Using Hyper-IL-6 and sgp130, we demonstrated that trans-signalling through gp130 is the dominant mechanism by which stromal-derived IL-6 protects MM cells from treatment-induced apoptosis, independent of membrane-bound IL-6R expression. Therefore, targeted inhibition of IL-6 trans-signalling with sgp130 could be used to suppress pathogenic effects in MM while preserving beneficial classical IL-6 signalling, offering a more precise and potentially safer alternative to total IL-6/IL-6R blockade. As disease progression increases trans-signalling through higher sIL-6R expression, early intervention in smouldering myeloma, before pathway amplification, may represent a more effective therapeutic strategy.

متن کامل اصلی

متن در JumpToDate ذخیره نشده است.

برای بررسی دسترسی کتابخانه‌ای یا خرید، رکورد اصلی را باز کنید.

رفتن به منبع اصلی

کلیدواژه‌ها

IL-6Mesenchymal stromal cellMultiple myelomaTrans-signallingsIL-6Rsgp130
در همین زیرشاخه

مقاله‌های مرتبط

PubMed2027

Clinical Flow Cytometric Testing in Chronic Lymphocytic Leukemia.

Flow cytometry is the cornerstone for establishing the diagnosis of chronic lymphocytic leukemia (CLL), owing to its characteristic and well-defined immunophenotype that enables accurate distinction from other leukemias and lymphomas. Beyond diagnosis, flow cytometry provides essential prognostic information and allows sensitive detection of minimal residual disease (MRD), a strong predictor of clinical outcome. CLL MRD assessment is i…

PubMed2027

Flow Cytometric Immunophenotyping of Acute Lymphoblastic Leukemia.

Immunophenotyping by flow cytometry is an important component in the diagnostic evaluation of patients with acute lymphoblastic leukemia. This technique further permits the detection of minimal residual disease after therapy, a robust prognostic factor that may guide individualized treatment. We describe here laboratory methods for both the initial characterization of lymphoblasts at diagnosis and the detection of rare leukemic lymphob…

PubMed2027

Immunophenotyping of Acute Myeloid Leukemia.

Immunophenotyping by multiparameter flow cytometry is a rapid and efficient technique to simultaneously assess and correlate multiple individual cell properties like size and internal complexity along with antigen expression in a population of cells. This method is utilized for rapid characterization of the blasts and classification of acute myeloid leukemia (AML) in both the peripheral blood (PB) and bone marrow (BM). This technique i…

PubMed2027

Measurable Residual Disease.

Measurable residual disease (MRD) serves as a critical biomarker of prognosis, treatment efficacy, and clinical outcome. It captures the presence of residual tumor cells below the detection threshold of conventional microscopy. Multiparametric flow cytometry (MFC) offers a rapid, cost-efficient, and widely applicable platform for MRD detection through leukemia-associated immunophenotypes (LAIPs) and deviation-from-normal (DfN) antigen …